4.5 Article

Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX™ adjuvanted recombinant antigens

Journal

VACCINE
Volume 28, Issue 14, Pages 2593-2597

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.01.018

Keywords

Pulmonary vaccination; ISCOMATRIX (TM) adjuvant; Recombinant antigens

Funding

  1. Australian Research Council [LP0347058]
  2. CSL Limited
  3. Australian Research Council [LP0347058] Funding Source: Australian Research Council

Ask authors/readers for more resources

Deep pulmonary delivery of an influenza ISCOMATRIX (TM) vaccine has previously been shown to induce a combined mucosal and systemic antibody response. To explore whether this combined response is influenced by intrinsic properties of the component antigen, we examined the efficacy of deep pulmonary delivery of ISCOMATRIX (TM) vaccines containing different recombinant antigens, specifically gB glycoprotein from cytomegalovirus and a fragment of catalase from Helicobacter pylori. Both these vaccines induced antigen-specific mucosal and systemic immunity, as well as antigen-specific proliferative cellular responses. Pulmonary immunisation with ISCOMATRIX (TM) vaccines may therefore be a generic way of inducing combined systemic and mucosal immunity. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available